Kronos Bio Announces Participation in Bank of America Securities 2021 Health Care Conference
Kronos Bio, Inc. (Nasdaq: KRON) will participate in a fireside chat at the Bank of America Securities 2021 Health Care Conference on May 13, 2021, at 1:15 p.m. ET. The event will be available via live webcast on the company's website, with a replay archived for one month. Kronos Bio focuses on developing therapies for cancer, with lead investigational therapy entospletinib aimed at treating NPM1-mutated acute myeloid leukemia (AML) and another candidate, KB-0742, targeting MYC-amplified solid tumors.
- Participation in a recognized healthcare conference potentially increases visibility and investor interest.
- Focus on innovative cancer therapies could enhance long-term growth prospects.
- None.
SAN MATEO, Calif. and CAMBRIDGE, Mass., May 06, 2021 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that members of the management team will participate in a fireside chat at the Bank of America Securities 2021 Health Care Conference on Thursday, May 13, 2021 at 1:15 p.m. ET.
The fireside chat will be webcast live from the Investors & Media section of the company’s website at www.kronosbio.com. A replay of the webcast will be archived and available for one month following the event.
About Kronos Bio, Inc.
Kronos Bio is a clinical-stage biopharmaceutical company dedicated to discovering and developing therapies that seek to transform the lives of those affected by cancer. The company focuses on targeting dysregulated transcription factors and the regulatory networks within cells that drive cancerous growth. Kronos Bio’s lead investigational therapy is entospletinib, a selective inhibitor targeting spleen tyrosine kinase (SYK) in development for the frontline treatment of NPM1-mutated acute myeloid leukemia (AML). The company is also developing KB-0742, an oral inhibitor of cyclin dependent kinase 9 (CDK9), for the treatment of MYC-amplified solid tumors.
Kronos Bio is based in San Mateo, Calif., and has a research facility in Cambridge, Mass. For more information, visit www.kronosbio.com or follow the company on LinkedIn.
Company contact:
Stephanie Yao
Executive Director, Investor Relations and Corporate Communications
650-525-6605
syao@kronosbio.com
Investors:
Claudia Styslinger
Argot Partners
212-600-1902
kronosbio@argotpartners.com
Media:
Sheryl Seapy
Real Chemistry
949-903-4750
sseapy@realchemistry.com
FAQ
What is Kronos Bio's lead therapy?
When will Kronos Bio participate in the Bank of America Securities Conference?
How can I watch the Kronos Bio fireside chat?
What other therapies is Kronos Bio developing?
